Cell Viability Assays Market Seen Reaching $2.72 Billion by 2030

The global cell viability assays market reached $1.73 billion in 2025 and is projected to hit $2.72 billion by 2030, according to The Business Research Company. Growth is being driven by cell-based therapeutics, drug discovery demand, and wider use of automated and imaging-based testing.

Why it matters: - Cell viability assays help researchers measure whether cells survive or recover after exposure to drugs, chemicals, or other stimuli. - The market’s growth reflects rising demand for tools that support drug discovery, toxicology testing, and cell therapy manufacturing. - The sector sits at the center of broader life sciences spending, especially in biomedical research and pharmaceutical development.

What happened: - The Business Research Company released its Cell Viability Assays Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report said the global cell viability assays market reached $1.73 billion in 2025. - The market is projected to rise to $1.91 billion in 2026. - The report forecasts the market will reach $2.72 billion by 2030.

The details: - The report puts 2025-2026 growth at a 10.5% compound annual growth rate. - It projects 2026-2030 growth at a 9.3% CAGR. - Recent growth has been driven by more in vitro research, higher pharmaceutical R&D spending, expanded toxicology testing, wider use of cell culture models, and standardized assay kits. - Future growth is expected to come from high-throughput drug discovery platforms, automated assay systems, and personalized medicine research. - The report points to assay miniaturization, imaging-based viability analysis, and deeper automation as major trends over the forecast period. - Cell viability assays are used to assess the ability of cells, tissues, or organs to survive or recover after exposure to stimuli. - The assays also help researchers determine optimal cell growth conditions and evaluate treatment effects. - Growing adoption of cell-based therapeutics is a major driver of demand. - These therapies use living cells to repair damaged tissue, treat disease, or restore biological function. - Advances in biotechnology, more funding for regenerative medicine, and better cell engineering techniques are expanding cell therapy use worldwide. - The report says viability assays are critical for monitoring therapeutic cell quality during manufacturing and clinical use. - The American Society of Gene & Cell Therapy reported a 10% increase in gene therapies entering Phase III clinical trials in Q3 2023. - North America led the market in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report also highlights market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables. - More information is available in the full report and a free sample.

Between the lines: - The market’s expansion tracks with broader shifts toward more automated, standardized, and higher-throughput life sciences workflows. - North America’s lead suggests established research infrastructure still anchors demand, while Asia-Pacific’s growth points to faster expansion in newer or scaling research markets. - The focus on cell-based therapeutics shows viability testing is becoming more important as advanced therapies move deeper into clinical development.

What's next: - The market is expected to keep expanding through 2030 as automation, miniaturization, and imaging-based analysis become more common. - Cell therapy development will likely remain a key demand driver as more products move through clinical testing and manufacturing.